Dataset from An Open-label Phase 1/2 Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009346
下载链接
链接失效反馈官方服务：
资源简介：
This is an open-label, multicenter, Phase 1/2 study of TAK-700 in combination with docetaxel
and prednisone that will evaluate the safety and pharmacokinetics (PK) of the combination and
will allow estimation of prostate-specific antigen (PSA) response in men with metastatic
castration-resistant prostate cancer (mCRPC).
创建时间：
2024-11-26
